SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 21, 2002; DOI 10.1182/blood-2002-01-0300. This Article Full Text (PDF) All Versions of this Article: 2002-01-0300v1 100/4/1399    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gorgun, G. Articles by Foss, F. M Search for Related Content PubMed PubMed Citation Articles by Gorgun, G. Articles by Foss, F. M Social Bookmarking                   What's this? Submitted January 30, 2002 Accepted April 10, 2002 Immunomodulatory effects of RXR rexinoids : Modulation of high affinity IL-2R expression enhances susceptibility to denileukin diftitox Gullu Gorgun and Francine M Foss* Hematology Oncology, Tufts New England Medical Center, Boston, MA, USA * Corresponding author; email: ffoss{at}lifespan.org. Rexinoids binding to both the RAR and RXR families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate both growth and differentiation-associated genes. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear. We explored the immunomodulatory effects of RAR and RXR rexinoids in human T and B-cell leukemia cells and demonstrated that RXR rexinoids are capable of upregulating high affinity IL-2R expression. Exposure to either 10-6 M to 10-10 M bexarotene or panretin for 48 hours was associated with increased expression of both the p55 and p74 subunits of the IL2R in T-cell leukemias and p75 in B-cell leukemias. Furthermore, rexinoid exposure enhanced susceptibility of the cells to denileukin diftitox fusion toxin targeting and intoxicating cells expressing high affinity IL-2R. These results suggest a rationale for combining rexinoids with IL2R targeted therapies in lymphoid malignancies as well as possibly in autoimmune diseases. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Rasooly, G. U. Schuster, J. P. Gregg, J.-H. Xiao, R. A. S. Chandraratna, and C. B. Stephensen Retinoid X Receptor Agonists Increase Bcl2a1 Expression and Decrease Apoptosis of Naive T Lymphocytes J. Immunol., December 15, 2005; 175(12): 7916 - 7929. [Abstract] [Full Text] [PDF] R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood, June 15, 2004; 103(12): 4636 - 4643. [Abstract] [Full Text] [PDF] S. Moqattash and J. D. Lutton Leukemia Cells and the Cytokine Network: Therapeutic Prospects Experimental Biology and Medicine, February 1, 2004; 229(2): 121 - 137. [Abstract] [Full Text] [PDF] A. E. Frankel, D. R. Fleming, P. D. Hall, B. L. Powell, J. H. Black, C. Leftwich, and R. Gartenhaus A Phase II Study of DT Fusion Protein Denileukin Diftitox in Patients with Fludarabine-refractory Chronic Lymphocytic Leukemia Clin. Cancer Res., September 1, 2003; 9(10): 3555 - 3561. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020